Your browser doesn't support javascript.
Coronavirus Disease 2019 (COVID-19) Diagnostic Clinical Decision Support: A Pre-Post Implementation Study of CORAL (COvid Risk cALculator).
Dugdale, Caitlin M; Rubins, David M; Lee, Hang; McCluskey, Suzanne M; Ryan, Edward T; Kotton, Camille N; Hurtado, Rocio M; Ciaranello, Andrea L; Barshak, Miriam B; McEvoy, Dustin S; Nelson, Sandra B; Basgoz, Nesli; Lazarus, Jacob E; Ivers, Louise C; Reedy, Jennifer L; Hysell, Kristen M; Lemieux, Jacob E; Heller, Howard M; Dutta, Sayon; Albin, John S; Brown, Tyler S; Miller, Amy L; Calderwood, Stephen B; Walensky, Rochelle P; Zachary, Kimon C; Hooper, David C; Hyle, Emily P; Shenoy, Erica S.
  • Dugdale CM; Division of Infectious Diseases, Massachusetts General Hospital, Boston, Massachusetts, USA.
  • Rubins DM; Medical Practice Evaluation Center, Massachusetts General Hospital, Boston, Massachusetts, USA.
  • Lee H; Harvard Medical School, Boston, Massachusetts, USA.
  • McCluskey SM; Harvard Medical School, Boston, Massachusetts, USA.
  • Ryan ET; Department of Medicine, Brigham & Women's Hospital, Boston, Massachusetts, USA.
  • Kotton CN; Mass General Brigham Clinical Informatics, Boston, Massachusetts, USA.
  • Hurtado RM; Harvard Medical School, Boston, Massachusetts, USA.
  • Ciaranello AL; Biostatistics Center, Massachusetts General Hospital, Boston, Massachusetts, USA.
  • Barshak MB; Division of Infectious Diseases, Massachusetts General Hospital, Boston, Massachusetts, USA.
  • McEvoy DS; Medical Practice Evaluation Center, Massachusetts General Hospital, Boston, Massachusetts, USA.
  • Nelson SB; Harvard Medical School, Boston, Massachusetts, USA.
  • Basgoz N; Division of Infectious Diseases, Massachusetts General Hospital, Boston, Massachusetts, USA.
  • Lazarus JE; Harvard Medical School, Boston, Massachusetts, USA.
  • Ivers LC; Division of Infectious Diseases, Massachusetts General Hospital, Boston, Massachusetts, USA.
  • Reedy JL; Harvard Medical School, Boston, Massachusetts, USA.
  • Hysell KM; Division of Infectious Diseases, Massachusetts General Hospital, Boston, Massachusetts, USA.
  • Lemieux JE; Harvard Medical School, Boston, Massachusetts, USA.
  • Heller HM; Division of Infectious Diseases, Massachusetts General Hospital, Boston, Massachusetts, USA.
  • Dutta S; Medical Practice Evaluation Center, Massachusetts General Hospital, Boston, Massachusetts, USA.
  • Albin JS; Harvard Medical School, Boston, Massachusetts, USA.
  • Brown TS; Division of Infectious Diseases, Massachusetts General Hospital, Boston, Massachusetts, USA.
  • Miller AL; Harvard Medical School, Boston, Massachusetts, USA.
  • Calderwood SB; Mass General Brigham Clinical Informatics, Boston, Massachusetts, USA.
  • Walensky RP; Division of Infectious Diseases, Massachusetts General Hospital, Boston, Massachusetts, USA.
  • Zachary KC; Harvard Medical School, Boston, Massachusetts, USA.
  • Hooper DC; Division of Infectious Diseases, Massachusetts General Hospital, Boston, Massachusetts, USA.
  • Hyle EP; Harvard Medical School, Boston, Massachusetts, USA.
  • Shenoy ES; Division of Infectious Diseases, Massachusetts General Hospital, Boston, Massachusetts, USA.
Clin Infect Dis ; 73(12): 2248-2256, 2021 12 16.
Article in English | MEDLINE | ID: covidwho-1592977
ABSTRACT

BACKGROUND:

Isolation of hospitalized persons under investigation (PUIs) for coronavirus disease 2019 (COVID-19) reduces nosocomial transmission risk. Efficient evaluation of PUIs is needed to preserve scarce healthcare resources. We describe the development, implementation, and outcomes of an inpatient diagnostic algorithm and clinical decision support system (CDSS) to evaluate PUIs.

METHODS:

We conducted a pre-post study of CORAL (COvid Risk cALculator), a CDSS that guides frontline clinicians through a risk-stratified COVID-19 diagnostic workup, removes transmission-based precautions when workup is complete and negative, and triages complex cases to infectious diseases (ID) physician review. Before CORAL, ID physicians reviewed all PUI records to guide workup and precautions. After CORAL, frontline clinicians evaluated PUIs directly using CORAL. We compared pre- and post-CORAL frequency of repeated severe acute respiratory syndrome coronavirus 2 nucleic acid amplification tests (NAATs), time from NAAT result to PUI status discontinuation, total duration of PUI status, and ID physician work hours, using linear and logistic regression, adjusted for COVID-19 incidence.

RESULTS:

Fewer PUIs underwent repeated testing after an initial negative NAAT after CORAL than before CORAL (54% vs 67%, respectively; adjusted odd ratio, 0.53 [95% confidence interval, .44-.63]; P < .01). CORAL significantly reduced average time to PUI status discontinuation (adjusted difference [standard error], -7.4 [0.8] hours per patient), total duration of PUI status (-19.5 [1.9] hours per patient), and average ID physician work-hours (-57.4 [2.0] hours per day) (all P < .01). No patients had a positive NAAT result within 7 days after discontinuation of precautions via CORAL.

CONCLUSIONS:

CORAL is an efficient and effective CDSS to guide frontline clinicians through the diagnostic evaluation of PUIs and safe discontinuation of precautions.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: Anthozoa / COVID-19 Type of study: Diagnostic study / Experimental Studies / Observational study / Prognostic study / Randomized controlled trials Limits: Animals / Humans Language: English Journal: Clin Infect Dis Journal subject: Communicable Diseases Year: 2021 Document Type: Article Affiliation country: Cid

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Anthozoa / COVID-19 Type of study: Diagnostic study / Experimental Studies / Observational study / Prognostic study / Randomized controlled trials Limits: Animals / Humans Language: English Journal: Clin Infect Dis Journal subject: Communicable Diseases Year: 2021 Document Type: Article Affiliation country: Cid